mitoNice
Nice Acropolis Congress Center Nice, FranceIn September, Abliva will attend mitoNice, an international congress dedicated to Mitochondrial Medicine.
Delivering mitochondrial health
In September, Abliva will attend mitoNice, an international congress dedicated to Mitochondrial Medicine.
In October, Abliva will attend the Italian patient organization Mitocon's annual Mitochondrial Diseases Conference in Rome, Italy. On October 8, Abliva's Chief Medical Officer Magnus Hansson will give the talk: An adaptive, clinical Phase 2/3 study evaluating the efficacy of KL1333 in adult primary mitochondrial disease patients in Session 5: Challenges and pitfalls in clinical […]
In late November, Abliva will attend the annual scientific conference Mitochondrial Medicine - Therapeutic Development in Hinxton, UK. Abliva's Chief Medical Officer, Magnus Hansson, will present a poster on one of the important preparatory studies for the upcoming, potentially registrational, Phase 2 study, FALCON, with KL1333 in patients with mitochondrial diseases.
In June, Abliva will attend this year's edition of Euromit - the international conference on mitochondrial disease. The meeting takes place in Bologna, Italy, and gathers researchers, clinicians, and patients for the sharing of knowledge and insights in the field. The conference also presents opportunities to meet with investigators in our FALCON study with KL1333.
In late June, Abliva will be attending this year's international Mitochondrial Medicine Symposium, organized by US patient organization United Mitochondrial Disease Foundation. The meeting will take place in Charlotte, North Carolina (US), on June 28 - July 1, and includes both scientific as well as patient and family sessions.
Abliva will participate at the 12th annual edition of 'The Future of Swedish & Danish Life Science', on September 7, 2023, in Lund, Sweden. The company's Chief Medical Officer, Magnus Hansson, will give a talk entitled Pivotal study design in a rare disease with no regulatory precedent – utilizing patient advocacy groups and registries. "The […]
During World Mitochondrial Disease Week, Abliva's Chief Medical Officer, Magnus Hansson, will present the company at the Cure Mito Foundation's Empower & Inspire - 2nd Annual Leigh Syndrome Symposium (virtual). See below for more information and the link to the event.
In mid-March, Abliva will attend the 8th edition of Mitochondrial Medicine - Therapeutic Development in Hinxton, UK. This annual scientific meeting is focused on mitochondrial disorders and the search for novel effective therapies. Abliva's CMO, Maguns Hansson, will join the panel discussion Challenges and opportunities in clinical trials: perspectives from pharma and funders, where representatives from […]
Join Abliva for a virtual KOL event featuring Amel Karaa, MD (Massachusetts General Hospital), who will discuss the unmet medical need and current treatment landscape for patients with primary mitochondrial disease. There are currently no approved medicines for the systemic disease. The event will focus on Abliva's lead program, KL1333, which has shown clinically meaningful, […]
In late June, Abliva will attend the US patient organization UMDF’s Mitochondrial Medicine Conference in Cleveland, Ohio. "Each year, UMDF’s Mitochondrial Medicine Conference brings together the best minds in mitochondrial medicine and the patients we serve. With over 700 attendees representing almost every state in the U.S. and more than 15 different countries, the Conference […]
In September, Abliva will attend the Nordic Life Science Days (NLS days) in Malmö, Sweden. Ablia's CEO, Ellen Donnelly, will be presenting the company at 11:00 a.m. CET on September 18, in the session Biotechnology. Follow the link below for more information.
In late October, Abliva will attend the 14th Mitochondrial Disease Conference, this year in Padua (IT), organized by the Italian patient organization Mitocon. Abliva's CMO, Magnus Hansson will attend the session: Roundtable with Pharmaceutical Industries and Regulatory Authorities. Read more by following the link below.